Figure 2
Figure 2. Survival and GVHD scores of B6D2 mice receiving TCD BM cells with or without Tn cells from WT B6 or CCR7−/− B6 donors with P815 murine mastocytoma cells. B6D2 recipients were lethally irradiated and then administered 3 × 106 TCD BM cells from WT B6 donors with or without 4 × 106 CD25-depleted Tn cells from either WT B6 or CCR7−/− B6 donors on day 0. In addition, all animals simultaneously received 25 000 P815 murine mastocytoma cells in the same inoculum. Data are combined from 2 separate transplantation experiments. n = 8 animals per group. (A) P = .001 for overall survival comparison between WT Tn cell/tumor and CCR7−/− Tn cell/tumor groups. (B) *P < .001 for comparison of GVHD scores.

Survival and GVHD scores of B6D2 mice receiving TCD BM cells with or without Tn cells from WT B6 or CCR7−/− B6 donors with P815 murine mastocytoma cells. B6D2 recipients were lethally irradiated and then administered 3 × 106 TCD BM cells from WT B6 donors with or without 4 × 106 CD25-depleted Tn cells from either WT B6 or CCR7−/− B6 donors on day 0. In addition, all animals simultaneously received 25 000 P815 murine mastocytoma cells in the same inoculum. Data are combined from 2 separate transplantation experiments. n = 8 animals per group. (A) P = .001 for overall survival comparison between WT Tn cell/tumor and CCR7−/− Tn cell/tumor groups. (B) *P < .001 for comparison of GVHD scores.

Close Modal

or Create an Account

Close Modal
Close Modal